Search

Blonanserin

Blonanserin is an atypical antipsychotic approved in Japan in January, 2008.

Eucalyptol

Eucalyptol is an ingredient in many brands of mouthwash and cough suppressant. It controls airway mucus hypersecretion and asthma via anti-inflammatory cytokine inhibition. … Eucalyptol is an effective treatment for nonpurulent rhinosinusitis. Eucalyptol reduces inflammation and pain when applied topically. It kills leukaemia cells in vitro.

Collagenase clostridium histolyticum

[L14882] The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ulcers. … Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum.

Geraniol

Due to its anticancer effects, geraniol has been found to be effective against a broad range of cancers including breast, lung, colon, prostate, pancreatic, skin, liver, kidney and oral cancers [A34262 … pharmacologic effects are clinically important as geraniol is classified as generally-recognized-as-safe (GRAS) by the Flavor and Extract Manufacturers Association (FEMA) and the Food and Drug Administration (FDA

Chromous sulfate

Artesunate

[A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099]

Dinutuximab

Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly … It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk

Aluminium phosphate

Fencamfamin

It is especially useful in patients with chronic conditions due to its favourable safety profile. … Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant.

Ruxolitinib

[A229938] Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. … [A229708] Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed.